VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ANTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ANTXAN2 Therapeutics, Inc.
$4.30$118M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksANTXQuarterly Financials

AN2 Therapeutics, Inc. (ANTX) Quarterly Financials

120+ quarters historyFree accessUpdated daily

AN2 Therapeutics, Inc. (ANTX) quarterly income statement — complete revenue, gross profit & net income history

ANTX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q1'21
Sales/Revenue0000000000000000000
Revenue Growth %-------------------
Cost of Goods Sold0000000000000000000
COGS % of Revenue-------------------
Gross Profit0000000000000000000
Gross Margin %-------------------
Gross Profit Growth %-------------------
Operating Expenses10.55M9.32M10.04M7.22M11.54M8.6M14.01M15.88M18.3M18.82M18.18M16.6M16.04M12.48M11.77M10.33M7.68M7.59M2.05M
OpEx % of Revenue-------------------
Selling, General & Admin3.81M2.44M3.04M4.02M3.85M3.21M3.48M3.73M3.64M3.9M3.75M3.06M4.05M3.72M3.34M3.63M2.05M1.78M401K
SG&A % of Revenue-------------------
Research & Development6.74M6.88M7M3.2M7.69M5.4M8.29M12.15M14.65M14.92M14.43M13.54M11.98M8.75M8.43M6.7M5.63M5.81M1.65M
R&D % of Revenue-------------------
Other Operating Expenses00000-9K1000K000000000000
Operating Income-10.55M-9.32M-10.04M-7.22M-11.54M-8.6M-14.01M-15.88M-18.3M-18.82M-18.18M-16.6M-16.04M-12.48M-11.77M-10.33M-7.68M-7.59M-2.05M
Operating Margin %-------------------
Operating Income Growth %8.55%-8.35%28.36%54.56%36.94%54.3%22.92%4.34%-14.07%-50.81%-54.46%-60.66%-108.76%-64.29%---274.78%--
EBITDA-10.03M-10M-9.35M-7.22M-11.54M9K-11.77M9.53M-18.3M-16.9M0-16.6M0-12.48M-11.77M-10.33M-7.68M0-2.05M
EBITDA Margin %-------------------
EBITDA Growth %13.08%-111244.44%20.54%-175.73%36.94%100.05%-157.39%--35.44%100%-60.66%100%----274.78%--
D&A (Non-Cash Add-back)000008.61M025.41M0018.18M016.04M00007.59M0
EBIT-10.03M-10M-9.35M-7.22M-11.54M-8.61M-11.77M-15.88M-18.3M-16.9M-18.18M-16.6M-16.04M-12.48M-11.77M-10.33M-7.68M-7.59M-2.05M
Net Interest Income523K605K687K754K888K0001.68M0000630K466K228K27K27K2K
Interest Income523K605K687K754K888K0001.68M0000630K466K228K27K27K2K
Interest Expense0000000000000000000
Other Income/Expense523K606K687K754K888K1.08M1.27M1.45M1.68M1.92M1.47M797K716K634K431K213K28K49K2K
Pretax Income-10.03M-8.71M-9.35M-6.46M-10.65M-7.52M-12.75M-14.44M-16.62M-16.9M-16.71M-15.8M-15.32M-11.84M-11.34M-10.12M-7.66M-7.54M-2.05M
Pretax Margin %-------------------
Income Tax0000000000000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Income-10.03M-8.71M-9.35M-6.46M-10.65M-7.52M-12.75M-14.44M-16.62M-16.9M-16.71M-15.8M-15.32M-11.84M-11.34M-10.12M-7.66M-7.54M-2.05M
Net Margin %-------------------
Net Income Growth %5.83%-15.79%26.63%55.23%35.91%55.49%23.7%8.66%-8.44%-42.7%-47.34%-56.17%-100.17%-56.95%---273.78%--
Net Income (Continuing)-10.03M-8.71M-9.35M-6.46M-10.65M-7.52M-12.75M-14.44M-16.62M-16.9M-16.71M-15.8M-15.32M-11.84M-11.34M-10.12M-7.66M-7.54M-2.05M
Discontinued Operations0000000000000000000
Minority Interest0000000000000000000
EPS (Diluted)-0.29-0.29-0.31-0.21-0.35-0.25-0.43-0.48-0.56-0.57-0.65-0.81-0.75-0.66-0.56-0.52-0.40-0.42-0.20
EPS Growth %17.14%-16%27.91%56.25%37.5%56.14%33.85%40.74%25.33%13.64%-16.07%-55.77%-87.5%-57.14%---100%--
EPS (Basic)-0.29-0.29-0.31-0.21-0.35-0.25-0.43-0.48-0.56-0.57-0.65-0.81-0.75-0.66-0.56-0.52-0.40-0.42-0.20
Diluted Shares Outstanding34.06M30.22M30.28M30.17M30.05M29.88M29.84M29.82M29.76M29.73M25.64M19.5M19.39M19.4M19.35M19.26M19M18.14M14.05M
Basic Shares Outstanding34.06M30.22M30.28M30.17M30.05M29.88M29.84M29.82M29.76M29.73M25.64M19.5M19.39M19.4M19.35M19.26M19M18.14M14.05M
Dividend Payout Ratio-------------------